The researchers said their findings could help scientists develop more targeted treatments for the disease. Previous studies have already found that, weighed against white women, dark women have a higher prevalence of breast cancers that usually do not react to hormone therapy – – so-called ‘triple-negative’ breast cancers. Now, the new study reviews that black breast tumor patients likewise have a ‘significantly higher prevalence of the TP53 driver mutation, basal tumor subtype and greater genomic diversity within tumors, all of which suggest more intense tumor biology,’ the study’s lead author, Dr. Tanya Keenan, of Massachusetts General Hospital Cancer Center in Boston, stated in a hospital news release. ‘The higher threat of tumor recurrence that we noticed among African American females was reduced when managing for all those factors, suggesting these genomic distinctions contribute, at least partly, to the known racial disparity in the survival of African American and Caucasian breast cancer patients,’ Keenan added.The assay methods HCV RNA amounts at baseline and during treatment and may be utilized to predict sustained and non-sustained virological response to HCV therapy. The outcomes from the RealTime HCV assay should be interpreted within the context of all relevant scientific and laboratory findings. The Abbott RealTime HCV assay isn’t for screening bloodstream, plasma, serum or cells donors for HCV, or to be used as a diagnostic check to confirm the presence of HCV disease. With the help of the HCV assay to its automated m2000 system, Abbott may be the just molecular diagnostics provider in the U.S., to offer viral load assays for HIV, HCV and HBV, and a combination check for gonorrhea and chlamydia, about the same molecular platform, said Joseph Jacobs, M.D., associate medical director, Abbott Molecular.